Shaolin Capital Management’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Shaolin Capital Management’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-15,100	Closed	-$147K	–	1016
2022 Q2	$147K	Hold	15,100	–	–	﹤0.01%	556
2022 Q1	$149K	Hold	15,100	–	–	﹤0.01%	602
2021 Q4	$150K	Hold	15,100	–	–	﹤0.01%	614
2021 Q3	$150K	Hold	15,100	–	–	﹤0.01%	476
2021 Q2	$151K	Sell	15,100 -184,900	-92%	-$1.85M	﹤0.01%	477
2021 Q1	$2.01M	Buy	+200,000	New	+$2M	0.08%	223

Other funds holding EBACU

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.34% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.72% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

Shaolin Capital Management's EBACU Position: Q3 2022 in Review

Shaolin Capital Management sold out of European Biotech Acquisition Corp. Units (EBACU) in Q3 2022, closing a stake of 15,100 shares — an estimated $147K sold.

Shaolin Capital Management first reported a position in EBACU in Q1 2021 and held it in 6 quarters. The position peaked at $2.01M in Q1 2021. 18 funds tracked by Wall St. Rank hold EBACU as of Q3 2022.

Shaolin Capital Management reported no remaining European Biotech Acquisition Corp. Units position as of Q3 2022 after selling out during the quarter.
Shaolin Capital Management sold 15,100 European Biotech Acquisition Corp. Units shares in Q3 2022, an estimated $147K.
Shaolin Capital Management first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 6 quarters.
Shaolin Capital Management's European Biotech Acquisition Corp. Units position peaked at $2.01M in Q1 2021.
18 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q3 2022.

Based on Shaolin Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.